Concordance in Histological and Biological Parameters Between First and Second Primary Breast Cancers

被引:43
作者
Huo, Dezheng [1 ]
Melkonian, Stephanie [1 ]
Rathouz, Paul J. [1 ]
Khramtsov, Andrey [2 ]
Olopade, Olufunmilayo I. [2 ]
机构
[1] Univ Chicago, Dept Hlth Studies, Dept Med, Chicago, IL 60637 USA
[2] Univ Chicago, Dept Med, Hematol Oncol Sect, Chicago, IL 60637 USA
基金
美国国家卫生研究院;
关键词
breast neoplasms; estrogen receptor; second primary neoplasm; tamoxifen; seer program; molecular epidemiology; HORMONE-RECEPTOR STATUS; ESTROGEN-RECEPTORS; TAMOXIFEN; PREVENTION; CARCINOMAS; OUTCOMES; CELLS;
D O I
10.1002/cncr.25587
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND: Women with breast cancer are more likely to have a second breast cancer than women in the general population are to have a primary cancer. However, the biological relationship between primary and second breast cancers is not clear. METHODS: A total of 30,617 patients diagnosed with bilateral breast cancers between 1990 and 2007 were identified through 17 cancer registries of the Surveillance, Epidemiology, and End Results program. Logistic regression with odds ratios (ORs) and 95% confidence intervals (CIs) was used to model strength of association in hormone receptor status, grade, and histology between 2 cancers. RESULTS: There was a strong association in estrogen receptor status between 2 bilateral tumors (OR, 7.64; 95% Cl, 7.00-8.35). The strength of association in estrogen receptor status depended on the time interval between the first and second tumors and age at diagnosis. The OR was 25.9 for synchronous tumors (within 1 month) and 3.69 for metachronous tumors separated by >= 10 years. The strength of association was stronger in patients whose first cancer was diagnosed before age 50 (OR, 11.7) versus after age 50 (OR, 5.71). A similar pattern was observed for progesterone receptor, grade, and histological type, but with relatively weaker association. CONCLUSIONS: The strong concordance in hormone receptor status of primary and second breast cancers suggests that 2 breast cancers arise in a common milieu and that tumor subtypes are predetermined in the early stage of breast carcinogenesis. Cancer 2011;117:907-15. (C) 2070 American Cancer Society.
引用
收藏
页码:907 / 915
页数:9
相关论文
共 25 条
[1]   Prospective identification of tumorigenic breast cancer cells [J].
Al-Hajj, M ;
Wicha, MS ;
Benito-Hernandez, A ;
Morrison, SJ ;
Clarke, MF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (07) :3983-3988
[2]   Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen [J].
Arpino, G ;
Weiss, HL ;
Clark, GM ;
Hilsenbeck, SG ;
Osborne, CK .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (21) :4687-4694
[3]   The descriptive epidemiology of second primary breast cancer [J].
Bernstein, JL ;
Lapinski, RH ;
Thakore, SS ;
Doucette, JT ;
Thompson, WD .
EPIDEMIOLOGY, 2003, 14 (05) :552-558
[4]   Is steroid receptor profile in contralateral breast cancer a marker of independence of the corresponding primary tumour? [J].
Coradini, D ;
Oriana, S ;
Mariani, L ;
Miceli, R ;
Bresciani, G ;
Marubini, E ;
Di Fronzo, G .
EUROPEAN JOURNAL OF CANCER, 1998, 34 (06) :825-830
[5]   Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy [J].
Cui, XJ ;
Schiff, R ;
Arpino, G ;
Osborne, CK ;
Lee, AV .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (30) :7721-7735
[6]   Overview of the main outcomes in breast-cancer prevention trials [J].
Cuzick, J ;
Powles, T ;
Veronesi, U ;
Forbes, J ;
Edwards, R ;
Ashley, S ;
Boyle, P .
LANCET, 2003, 361 (9354) :296-300
[7]   Breast cancer, stem/progenitor cells and the estrogen receptor [J].
Dontu, G ;
El-Ashry, D ;
Wicha, MS .
TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2004, 15 (05) :193-197
[8]   Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study [J].
Fisher, B ;
Costantino, JP ;
Wickerham, DL ;
Redmond, CK ;
Kavanah, M ;
Cronin, WM ;
Vogel, V ;
Robidoux, A ;
Dimitrov, N ;
Atkins, J ;
Daly, M ;
Wieand, S ;
Tan-Chiu, E ;
Ford, L ;
Wolmark, N .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (18) :1371-1388
[9]   Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer [J].
Foulkes, WD ;
Stefansson, IM ;
Chappuis, PO ;
Bégin, LR ;
Goffin, JR ;
Wong, N ;
Trudel, M ;
Akslen, LA .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (19) :1482-1485
[10]   Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics [J].
Garcia-Closas, Montserrat ;
Hall, Per ;
Nevanlinna, Heli ;
Pooley, Karen ;
Morrison, Jonathan ;
Richesson, Douglas A. ;
Bojesen, Stig E. ;
Nordestgaard, Borge G. ;
Axelsson, Christen K. ;
Arias, Jose I. ;
Milne, Roger L. ;
Ribas, Gloria ;
Gonzalez-Neira, Anna ;
Benitez, Javier ;
Zamora, Pilar ;
Brauch, Hiltrud ;
Justenhoven, Christina ;
Hamann, Ute ;
Ko, Yon-Dschun ;
Bruening, Thomas ;
Haas, Susanne ;
Doerk, Thilo ;
Schuermann, Peter ;
Hillemanns, Peter ;
Bogdanova, Natalia ;
Bremer, Michael ;
Karstens, Johann Hinrich ;
Fagerholm, Rainer ;
Aaltonen, Kirsimari ;
Aittomaki, Kristiina ;
Von Smitten, Karl ;
Blomqvist, Carl ;
Mannermaa, Arto ;
Uusitupa, Matti ;
Eskelinen, Matti ;
Tengstrom, Maria ;
Kosma, Veli-Matti ;
Kataja, Vesa ;
Chenevix-Trench, Georgia ;
Spurdle, Amanda B. ;
Beesley, Jonathan ;
Chen, Xiaoqing ;
Devilee, Peter ;
Van Asperen, Christi J. ;
Jacobi, Catharina E. ;
Tollenaar, Rob A. E. M. ;
Huijts, Petra E. A. ;
Klijn, Jan G. M. ;
Chang-Claude, Jenny ;
Kropp, Silke .
PLOS GENETICS, 2008, 4 (04)